Plasma donations go to patients with immune deficiencies, bleeding disorders, severe burns, liver disease, and a range of autoimmune and neurological conditions. Most donated plasma isn’t transfused directly into a patient. Instead, it’s processed into specific medical products, each one targeting a different condition. It takes more than 130 individual plasma donations per year to treat just one patient with a primary immunodeficiency, and a single dose of the antibody therapy they depend on requires 10 to 40 donations to produce.
People With Immune Deficiencies
The single largest group of plasma recipients are people whose immune systems can’t produce enough antibodies on their own. Primary immunodeficiency is a group of more than 400 genetic conditions where the body fails to fight infections effectively. Without treatment, even a common cold or sinus infection can become dangerous. These patients receive immunoglobulin therapy, a concentrated antibody product manufactured from pooled plasma. Each batch is made from 1,000 or more individual donations to ensure it contains a broad spectrum of antibodies against many different pathogens.
Secondary immune deficiencies also drive demand. These develop later in life as a result of other conditions or treatments, such as certain cancers, organ transplants, or medications that suppress the immune system. For both groups, immunoglobulin therapy is not a cure. It’s a lifelong replacement for what the body can’t make, delivered through regular infusions every few weeks.
Patients With Bleeding Disorders
Hemophilia A and hemophilia B are inherited conditions where the blood lacks specific clotting factors. Without these proteins, even minor injuries can cause prolonged or internal bleeding. Plasma-derived clotting factor concentrates replace what’s missing, allowing patients to control and prevent bleeding episodes. Some patients use these products on demand when bleeding occurs, while others receive them on a regular schedule as preventive treatment.
While synthetic (recombinant) clotting factors now exist for some patients, plasma-derived versions remain essential for others, particularly those who develop resistance to synthetic alternatives or who need a broader mix of clotting proteins.
Burn and Trauma Survivors
Severe burns cause massive plasma loss. In the early shock stage of a burn injury, fluid leaks from damaged capillaries into surrounding tissue and out through the wound surface, rapidly depleting blood volume. Fresh frozen plasma is transfused directly to restore circulating volume, prevent dangerous swelling and fluid buildup, and reduce the risk of lung complications. For patients with major burns, plasma transfusion is a core part of resuscitation.
Trauma patients experiencing massive hemorrhage from accidents, surgery, or combat injuries also receive plasma transfusions. In these cases, plasma helps restore the blood’s ability to clot, working alongside red blood cell transfusions to stabilize patients who are losing blood faster than their body can compensate.
People With Liver Disease
The liver produces albumin, the most abundant protein in blood plasma. Albumin maintains fluid balance by keeping water inside blood vessels rather than letting it leak into surrounding tissues. When the liver fails, albumin levels drop, and fluid accumulates in the abdomen (a condition called ascites) and other areas of the body.
Plasma-derived albumin is a frontline treatment for several complications of advanced cirrhosis. When doctors drain large volumes of fluid from the abdomen, albumin infusions prevent a dangerous drop in blood pressure and circulation that can follow the procedure. In patients who develop bacterial infections of that abdominal fluid, combining albumin with antibiotics cuts the risk of kidney failure and reduces mortality from roughly 29% to 10%. Albumin also plays a role in diagnosing and treating kidney injury in cirrhosis patients, where it helps restore blood flow to the kidneys.
Beyond simple volume replacement, albumin acts as an antioxidant and detoxifier, binding harmful molecules and helping regulate inflammation. Ongoing albumin therapy is increasingly recognized as a treatment that can slow disease progression in decompensated cirrhosis, not just manage individual crises.
Neurological and Autoimmune Conditions
High-dose immunoglobulin therapy has a different effect than the replacement doses given to immune-deficient patients. At higher concentrations, it calms an overactive immune system rather than boosting a weak one. This makes it valuable for autoimmune and inflammatory diseases where the body’s defenses attack its own tissues.
One key example is chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a rare condition where the immune system damages the protective coating on nerves. This causes progressive weakness and numbness, often in the legs and arms. Immunoglobulin delivered through an IV is recommended as a first-line treatment. Patients typically receive an initial loading dose over several days, followed by maintenance infusions every three weeks to keep symptoms in check. Some patients later switch to injections under the skin for ongoing treatment.
Similar immunoglobulin therapy is used across a growing number of neurological, blood, and skin disorders where immune dysregulation is the underlying problem. For many of these conditions, plasma-derived immunoglobulin remains the most effective or only available treatment.
How Many Donations It Takes
The sheer volume of plasma required to treat these conditions is what makes donation so critical. A single patient with a primary immunodeficiency needs the equivalent of more than 130 donations every year, for life. Manufacturing a single batch of immunoglobulin can require anywhere from 1,500 to 50,000 units of plasma, depending on the product and batch size. Each batch is pooled from hundreds or thousands of donors to ensure consistency and a broad antibody profile.
Clotting factor concentrates, albumin, and other plasma-derived products each have their own manufacturing requirements, but they all start with the same raw material: donated human plasma. No synthetic substitute exists for most of these products. The patients who depend on them are entirely reliant on a steady supply of donors.